• LAST PRICE
    3.5700
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    3.3000/ 5
  • Ask / Lots
    3.6300/ 1
  • Open / Previous Close
    3.4200 / 3.5700
  • Day Range
    Low 3.3720
    High 3.6200
  • 52 Week Range
    Low 2.6100
    High 27.3500
  • Volume
    271,739
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 3.43
TimeVolumeRAPT
09:32 ET45673.43
09:34 ET9403.43
09:36 ET18783.47
09:38 ET1593.47
09:43 ET3003.465
09:45 ET7003.47
09:48 ET7003.45
09:50 ET27003.42
09:52 ET10613.41
09:57 ET47903.3845
09:59 ET14803.38
10:06 ET1003.39
10:10 ET7573.39
10:12 ET1003.39
10:15 ET23003.435
10:17 ET12003.41
10:19 ET4003.42
10:21 ET1003.43
10:24 ET3003.43
10:26 ET1003.43
10:28 ET2003.43
10:32 ET16453.46
10:35 ET1003.47
10:42 ET20983.48
10:44 ET4003.445
10:46 ET4963.44
10:48 ET3003.46
10:50 ET5003.46
10:51 ET4223.475
10:55 ET3003.48
11:02 ET9003.49
11:04 ET1003.485
11:06 ET3873.49
11:08 ET1003.49
11:09 ET1003.49
11:13 ET31123.445
11:15 ET7003.48
11:20 ET9003.46
11:22 ET24003.475
11:24 ET1003.48
11:26 ET9003.48
11:27 ET1003.46
11:29 ET23003.455
11:31 ET21003.45
11:33 ET35963.46
11:36 ET104713.44
11:38 ET1003.445
11:40 ET10003.46
11:42 ET5003.46
11:44 ET1003.47
11:47 ET1003.475
11:49 ET25003.53
11:56 ET1003.54
11:58 ET10003.5551
12:00 ET1003.555
12:02 ET4003.56
12:03 ET7533.575
12:05 ET31813.615
12:07 ET6493.6001
12:09 ET5993.6011
12:12 ET30003.535
12:14 ET4003.54
12:16 ET27333.51
12:18 ET4003.52
12:20 ET2003.52
12:21 ET3003.52
12:23 ET9123.53
12:27 ET8003.53
12:30 ET1003.53
12:32 ET4003.52
12:38 ET1123.5
12:39 ET17743.515
12:41 ET2003.52
12:43 ET23003.48
12:52 ET2003.48
12:56 ET1003.48
12:57 ET1003.485
12:59 ET3003.48
01:01 ET9013.46
01:03 ET7193.465
01:06 ET3003.47
01:08 ET2003.485
01:14 ET1003.485
01:17 ET6043.49
01:21 ET1003.49
01:32 ET1003.47
01:35 ET10003.46
01:37 ET12003.46
01:39 ET1183.47
01:42 ET1023.47
01:46 ET2003.47
01:48 ET2003.47
01:50 ET1003.47
01:53 ET1003.47
01:57 ET1003.47
02:02 ET1003.46
02:04 ET10243.5
02:06 ET1003.505
02:11 ET2003.5
02:13 ET2133.5
02:18 ET4503.49
02:22 ET6003.49
02:24 ET6003.51
02:26 ET11043.5
02:27 ET4003.515
02:33 ET3003.515
02:38 ET1003.52
02:40 ET3343.52
02:42 ET11273.51
02:44 ET30323.5268
02:47 ET9003.53
02:49 ET50003.5399
02:51 ET14503.53
02:56 ET4003.51
02:58 ET1003.51
03:00 ET9423.51
03:02 ET6753.51
03:03 ET2003.5
03:05 ET5263.525
03:18 ET1003.525
03:21 ET1003.525
03:23 ET22003.55
03:25 ET1003.555
03:27 ET126843.59
03:30 ET4003.59
03:32 ET3003.59
03:34 ET3133.59
03:36 ET2003.59
03:38 ET35013.61
03:39 ET45083.6
03:41 ET15593.591
03:43 ET7003.61
03:45 ET38923.61
03:48 ET7003.61
03:50 ET25703.6
03:52 ET1003.6
03:54 ET26393.5801
03:56 ET13603.57
03:57 ET23753.58
03:59 ET466413.57
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRAPT
RAPT Therapeutics Inc
119.4M
-1.2x
---
United StatesTVGN
Tevogen Bio Holdings Inc
118.8M
-1,650.9x
---
United StatesNVCT
Nuvectis Pharma Inc
120.8M
-4.7x
---
United StatesXFOR
X4 Pharmaceuticals Inc
117.9M
-1.0x
---
United StatesATYR
aTyr Pharma Inc
120.1M
-2.0x
---
United StatesRLMD
Relmada Therapeutics Inc
122.5M
-1.2x
---
As of 2024-07-16

Company Information

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.

Contact Information

Headquarters
561 Eccles AveSOUTH SAN FRANCISCO, CA, United States 94080-1906
Phone
650-489-9000
Fax
302-531-3150

Executives

Independent Chairman of the Board
William Rieflin
President, Chief Executive Officer, Director
Brian Wong
Chief Financial Officer
Rodney Young
Chief Scientific Officer
Dirk Brockstedt
Chief Medical Officer
William Ho

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$119.4M
Revenue (TTM)
$0.00
Shares Outstanding
34.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.23
EPS
$-3.07
Book Value
$4.27
P/E Ratio
-1.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.